|
Age (years)
|
61.0 (8.7)
|
60.3 (9.1)
|
|
Male, N (%)
|
140 (68)
|
141 (68)
|
|
Body mass indexa
|
32.3 (4.2)
|
32.1 (4.2)
|
|
Smokers, N (%)
|
36 (18)
|
27 (13)
|
|
Median (IQR) alcohol consumption (units/week)
|
2 (0;6)
|
1 (0;5)
|
|
Duration of type 2 diabetes (years)
|
13.5 (6.2)
|
12.2 (6.5)
|
|
HbA1c (%)
|
8.6 (1.1)
|
8.5 (1.0)
|
|
HbA1c (mmol/mol)
|
70 (12)
|
69 (11)
|
|
LDL cholesterol (mmol/l)
|
2.2 (0.8)
|
2.2 (0.8)
|
|
eGFRb (mL/min)
|
130 (44)
|
126 (45)
|
|
Vitamin B12 (pmol/l)
|
283 (200; 369)
|
275 (222; 359)
|
|
Methyl malonic acid (µmol/l)
|
0.20 (0.15; 0.25)
|
0.21 (0.16; 0.27)
|
|
Diabetic complications
|
|
Symptomatic autonomous neuropathy N (%)
|
33 (16)
|
36 (18)
|
|
Symptomatic peripheral neuropathy N (%)
|
76 (37)
|
78 (38)
|
|
Prior cardiovascular disease N (%)c
|
45 (22)
|
55 (27)
|
|
Microalbuminuria N (%)
|
48 (24)
|
40 (20)
|
|
Macroalbuminuria N (%)
|
12 (6)
|
8 (4)
|
|
Simplex retinopathy N (%)
|
59 (30)
|
63 (31)
|
|
Proliferative retinopathy N (%)
|
15 (8)
|
10 (5)
|
|
Medication at baseline
|
|
RAS blockade N (%)
|
159 (77)
|
149 (72)
|
|
Beta blocker N (%)
|
41 (10)
|
42 (10)
|
|
Acetylsalicylic acid
|
103 (54.5)
|
109 (59.6)
|
|
Diuretics N (%)
|
74 (18)
|
71 (17)
|
|
Statin N (%)
|
170 (83)
|
181 (88)
|
